Skip to main content
NCBI home page
Heart logoLink to Heart
. 1997 Nov;78(5):505–508. doi: 10.1136/hrt.78.5.505

Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy

Y Sato 1, K Kataoka 1, A Matsumori 1, S Sasayama 1, T Yamada 1, H Ito 1, Y Takatsu 1
PMCID: PMC1892299  PMID: 9415013

Abstract

Objective—To identify new prognostic indicators in idiopathic dilated cardiomyopathy (DCM) and secondary cardiomyopathy.
Design and patients—Serum concentrations of aminoterminal propeptides of type III procollagen and the 7S domain of type IV collagen (7S collagen)—which have recently been used as indicators of collagen matrix turnover in other diseases—and of cardiac troponin T were measured in 17 consecutive patients with DCM and in four patients with secondary cardiomyopathy (one associated with hyperthyroidism, two with chronic renal failure, one with amyloidosis), confirmed by endomyocardial biopsy. The correlation of these variables with short term prognosis was then assessed prospectively.
Results—11 of the patients were positive for type III procollagen, 7S collagen, or troponin T even though their creatine kinase concentrations were within the normal range. These patients had a poor short term prognosis (p < 0.001).
Conclusions—Within the DCM and secondary cardiomyopathy groups, there was a subgroup of patients with raised concentrations of serum collagen and troponin T, for whom short term prognosis was poor. Although it is unclear whether these serum peptide levels reflect ongoing myocyte degeneration and interstitial fibrosis, they may serve as useful new prognostic indicators for cardiomyopathy.

 Keywords: troponin T;  collagen;  dilated cardiomyopathy

Full Text

The Full Text of this article is available as a PDF (78.6 KB).

Figure 1  .

Figure 1  

Open in a new tab

Rate of freedom from cardiac events. The event-free rate in patients seronegative for type III procollagen, 7S collagen, or troponin T was significantly higher than in seropositive patients on day 216 (p < 0.001).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aretz H. T., Billingham M. E., Edwards W. D., Factor S. M., Fallon J. T., Fenoglio J. J., Jr, Olsen E. G., Schoen F. J. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987 Jan;1(1):3–14. [PubMed] [Google Scholar]
  2. Dec G. W., Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med. 1994 Dec 8;331(23):1564–1575. doi: 10.1056/NEJM199412083312307. [DOI] [PubMed] [Google Scholar]
  3. Díez J., Laviades C., Mayor G., Gil M. J., Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation. 1995 Mar 1;91(5):1450–1456. doi: 10.1161/01.cir.91.5.1450. [DOI] [PubMed] [Google Scholar]
  4. Epstein S. E., Rosing D. R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981 Sep;64(3):437–441. doi: 10.1161/01.cir.64.3.437. [DOI] [PubMed] [Google Scholar]
  5. Mason J. W., O'Connell J. B., Herskowitz A., Rose N. R., McManus B. M., Billingham M. E., Moon T. E. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995 Aug 3;333(5):269–275. doi: 10.1056/NEJM199508033330501. [DOI] [PubMed] [Google Scholar]
  6. Matsumori A., Kawai C., Yamada T., Ohkusa T., Morishima S., Tamaki N., Watanabe Y., Yonekura Y., Endo K., Konishi J. Mechanism and significance of myocardial uptake of antimyosin antibody in myocarditis and cardiomyopathy: clinical and experimental studies. Clin Immunol Immunopathol. 1993 Aug;68(2):215–219. doi: 10.1006/clin.1993.1121. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES